Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial

Ads

You May Also Like

Profound Medical Announces Second Quarter 2018 Financial Results

TORONTO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or ...

Paratek Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

BOSTON, March 16, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that ...

Ligase Enzyme Market: Application and Opportunity Analysis by 2026

Latest report published by Progressive Markets on global ligase enzyme market is expected to ...